Product
Merlin™ Assay (CE-IVD)
The Merlin™ Assay incorporates clinicopathologic variables (age and Breslow thickness) to the gene expression profiling component to accurately predict the risk of nodal metastasis in primary cutaneous melanoma patients. Low-risk patients may forgo the sentinel lymph node biopsy (SLNB). The non-invasive Merlin™ Assay does not require an additional procedure for the patient as it uses primary tumor tissue* that was collected for the melanoma diagnosis.
DOWNLOAD BROCHURE:
